latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/uk-s-nice-recommends-axonics-device-to-treat-overactive-bladders-57093603 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

UK's NICE recommends Axonics' device to treat overactive bladders

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


UK's NICE recommends Axonics' device to treat overactive bladders

The U.K.'s National Institute for Health and Care Excellence recommended Axonics Modulation Technologies Inc.'s rechargeable wireless device for treating overactive bladders.

About 19% of the U.K.'s population has an overactive bladder, according to NICE. The disorder's symptoms include needing to pass urine frequently with or without an uncontrollable urge, with women and the elderly the most affected.

Axonics' implant is the first rechargeable sacral neuromodulation system to be approved for sale in the U.S., Europe, Canada and Australia.

The U.K. agency gave the nod to the company's sacral neuromodulation implant to treat patients with issues related to urinary retention. The device stimulates nerves associated with bladder function with electric current via an electrode attached to an implantable pulse generator and aims to make the bladder work in a more controllable way.

NICE said the device costs about £9,660. Current data indicates that the implant's battery will last for about six years before it needs to be replaced, but there is some evidence to suggest it could last as long as 15 years, the agency added.

The agency's cost modeling suggests that the device becomes cost saving compared with the current non-rechargeable system at the six-year mark. Assuming a 15-year life span for the implant, NICE believes the implant has the potential to save the National Health Service around £6,200 per patient.